LSL Pharma Group Engages Paradox as Investor Relations Services Provider
October 06 2023 - 6:30AM
LSL Pharma Group Inc. (TSXV: LSL) – (the “
Company”
or “
LSL Pharma Group”), a Canadian integrated
pharmaceutical company, is pleased to announce that it has retained
on October 5, 2023 the services of Paradox Public Relations Inc.
(“
Paradox”) to provide investor relations services
on behalf of the Company. Paradox is a Montréal-based investor
relations consultancy firm that has been in business for over 20
years. Paradox will focus on developing and expanding the Company’s
communications and visibility with the investment community through
a comprehensive investor relations program.
The Investor Relations Agreement has a term of
12 months and can be terminated at any time without charge by
either party by giving 30 days’ notice in writing. Paradox will be
paid a monthly fee of $10,000, plus applicable taxes, and are
granted stock options to acquire up to 300,000 Class A shares of
the Company at a price of $0,70 per share, which options shall be
for a period of 10 years and vest in four equal tranches, quarterly
over a twelve (12) months period, the whole in accordance with the
current stock option plan of the Company and Policy 3.4 of the
TSXV. The Investor Relations Agreement as well as the professional
engagement fees and granting of the stock options remains subject
to TSX Venture Exchange approval.
ABOUT LSL PHARMA GROUP
INC.
LSL Pharma Group is a Canadian integrated
pharmaceutical company specializing in the development,
manufacturing and distribution of high-quality natural health
products and dietary supplements in solid dosage forms, as well as
high quality sterile ophthalmic pharmaceutical products. For more
information, please visit www.laboratoirelsl.com and
www.sterimedpharma.com.
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
CONTACT:François Roberge,
President and Chief Executive Officer Telephone: 514-664-7700Email:
Investors@groupelslpharma.com
LSL Pharma (TSXV:LSL)
Historical Stock Chart
From Mar 2024 to Apr 2024
LSL Pharma (TSXV:LSL)
Historical Stock Chart
From Apr 2023 to Apr 2024